Use of a Smart-phone Based Medication Adherence Platform to Improve Outcomes in Uncontrolled Non-insulin Dependent Diabetes Among Veterans

VA Sierra Nevada Health Care System

Status: Completed

Conditions: Diabetes; Diabete Type 2

Treatments: Behavioral: Dayamed Arthur a novel intelligent medication adherence platform

Study type: Interventional

Funder types: Other U.S. Federal agency

Identifiers

NCT05789706

1655381

Details and patient eligibility

About

The purpose of this study is to determine if a novel smartphone-based medication adherence platform accompanied by directed pharmacist intervention can improve A1c control and medication compliance in non-insulin dependent diabetics.

Full description

This study will employ a case-crossover design where patients will undergo both a standard of care arm as well as an intervention arm (See Figure 1). Half of the study participants will be randomized and enrolled in the standard of care arm for the initial 3 months and then transition to the intervention arm for 3 months. The remaining patients will be enrolled in the intervention arm for the initial 3 months and then transitioned to the standard of care arm.

Primary outcomes will be the change from pre-intervention baseline in hemoblobin A1c (HgA1c) between the Dayamed Arthur platform and standard of care.

Secondary outcomes will include change in MAS, the change in RMA from week 1 of intervention arm to week 12, comparison of historical MPR and PDC with patient's RMA at week 1 of intervention arm, and correlation of change in RMA and MAS score during intervention arm. Furthermore, we will measure sustained change in MAS in the patient population who begin study in the intervention arm and are subsequently transitioned to standard of care. We will also collect information patient usability/acceptability and provider satisfaction with the Dayamed Arthur platform.

Exploratory outcomes will include potential reduction in healthcare resource utilization based on avoidance of therapy escalation in patients with improved compliance, as well as psychosocial factors associated with improved adherence

Reduction of HgbA1c by 0.5% from pre-intervention baseline for individuals on the DayaMed intervention compared to standard of care

Enrollment: 30 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Assigned primary care provider at VA Sierra Nevada Healthcare System (VASNHCS)

• Diagnosis of type 2 diabetes

• Own a smart phone/tablet

• HgbA1c drawn at or within 30 days of study enrollment.

• Uncontrolled A1c defined as an A1c >9 in the following order of preference

  • Last 3 A1cs >9% in the last 2 year
  • Last 2 A1cs >9% in the last 2 years
  • Last A1c >9% in the last 2 years
  • 2-year average A1c >9%

Exclusion criteria

• Actively on insulin therapy
• Unable to install DayaMed application onto their phone/tablet
• Unable to load medications

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

30 participants in 2 patient groups

Intervention Arm

Experimental group

Description:

Patients will have Dayamed Arthur a novel intelligent medication adherence platform installed on their smartphone and configured with their pharmacy data providing accurate prompts and reminders to patients to take medications as directed In addition to the prompts patient all auditable information will be relayed to their PACT CPS through a provider dashboard allowing for timely and directed clinical intervention. Dayamed Arthur will provide automated alerts to the patients care team in specific scenarios.

Treatment:

Behavioral: Dayamed Arthur a novel intelligent medication adherence platform

Standard of Care Arm

No Intervention group

Description:

Study subjects will be counseled on medication adherence and strategies to remember how to take their medications correctly. Study subjects will then be followed as clinically indicated by their clinical care team.